JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 53(2019) N 6 p. 896-903; DOI 10.1134/S0026893319060104 Full Text

S.A. Kozin1*, A.A. Makarov1

The Convergence of Alzheimer's Disease Pathogenesis Concepts

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia

*kozinsa@gmail.com
Received - 2019-06-17; Revised - 2019-07-15; Accepted - 2019-07-15

Advances in the research of molecular factors involved in the onset and progression of Alzheimer's disease, have led to the creation of several pathogenesis concepts of the most common neurodegenerative disease in the world, and amyloid, cholinergic, and neuroinflammatory hypotheses became leading. Over past twenty years, based on these hypotheses, hundreds of drug prototypes were developed, but none of them were able to stop the development of Alzheimer's disease. In this review, based on the latest experimental data on structure-function properties of chemically modified amyloid-beta isoforms, the concept of the origin and the mechanism of action of amyloid-beta with isomerized Asp7 residue, as a molecular agent of Alzheimer's disease pathogenesis, is presented. This concept makes it possible not only to combine the most important aspects of existing hypotheses but also indicates ways of creating agents for fighting Alzheimer's disease with a principally new mechanism of action, "disease-modifying drugs."

Alzheimer's disease, amyloid-beta, isoaspartate, cerebral amyloidogenesis, amyloid plaques, neuroinflammation, neurodegeneration, α4β2 subtype nicotinic acetylcholine receptor



JMB-FOOTER RAS-JOURNALS